Integrating Superior Hypogastric Plexus Block with Conventional Therapies: Advancements in Chronic Pelvic Pain Management.

Chronic pelvic pain (CPP) is a persistent and debilitating condition that significantly impacts individuals’ quality of life. It is characterized by pain in the pelvic region lasting 6 months or longer, often unrelated to menstrual cycles or identifiable pathological causes.[ 1 ] CPP is a prevalent condition, affecting approximately 15–20% of women globally, and is associated with a variety of etiologies, including gynecological, urological, gastrointestinal, and musculoskeletal disorders. In men, while less common, CPP can manifest as chronic prostatitis or chronic pelvic pain syndrome, affecting both functional and psychological wellbeing.[ 2 ] The chronic nature of CPP not only leads to ongoing physical discomfort but also results in substantial emotional and psychological distress. Many individuals with CPP experience limitations in daily activities, reduced work productivity, and a significant decline in social and recreational engagement.[ 3 ] The condition is often linked with comorbidities such as anxiety, depression, and sleep disturbances, which exacerbate the overall burden of the disease. Consequently, CPP poses a considerable challenge to healthcare providers, necessitating a nuanced understanding of its multifactorial origins and a multidisciplinary approach to management.[ 3 ] The ultimate goal is to establish a multimodal approach that maximizes therapeutic efficacy while minimizing adverse effects, thereby improving the overall quality of life for patients suffering from CPP. The SHPB is an interventional technique designed to manage CPP by interrupting nociceptive pathways. This procedure involves the injection of anesthetic agents around the SHP, a retroperitoneal structure located anterior to the L5 vertebral body and the sacral promontory. By targeting this plexus, clinicians aim to disrupt the transmission of pain signals originating from the pelvic viscera, thereby providing relief to patients suffering from chronic pelvic pain conditions.[ 4 ] The pharmacodynamics of SHPB primarily depend on the anesthetic agents employed in the procedure. Commonly used agents include bupivacaine and lidocaine. The mechanisms of action of the superior hypogastric plexus block in chronic pelvic pain management are summarized in Table 1 . Mechanism of action of superior hypogastric plexus block in chronic pelvic pain management Numerous clinical trials have established the efficacy of the SHPB in managing CPP.[ 13 ] First described by Plancarte et al .[ 4 ] in 1990, SHPB was introduced as a treatment for cancer-related CPP, demonstrating a remarkable 70% reduction in pain levels. Subsequently, de Leon-Casasola et al .[ 14 ] reported a 69% success rate with bilateral SHPB in patients with cancer-related CPP who had not adequately responded to opioid therapy. Over the years, SHPB has been applied to various female pelvic pain syndromes, including interstitial cystitis, urethral pain, and endometriosis. For instance, Weschler et al . used SHPB for chronic endometriosis in six patients, with five experiencing significant pain relief and no complications.[ 1 ] Comparative studies further underscore the effectiveness of SHPB relative to other nerve blocks. A randomized clinical trial conducted by Amin et al .[ 15 ] compared the efficacy of SHPB with acupuncture for idiopathic CPP, finding that SHPB achieved a success rate of 72.6%, significantly surpassing acupuncture in pain reduction. SHPB is equally effective as impar ganglion block (IGB) in alleviating CPP symptoms, although IGB may present a safer alternative for certain patients. SHPB is indicated for a range of conditions associated with chronic pelvic pain, including endometriosis, interstitial cystitis, urethral pain syndromes, and cancer-related pelvic pain. The selection of appropriate patients is crucial for optimizing treatment outcomes. These factors include the underlying cause of the CPP—such as the severity of endometriosis—and the patient’s response to the initial diagnostic block. Additionally, the absence of structural pathology is critical in predicting favorable outcomes.[ 16 ] The integration of the SHPB into conventional therapies for managing CPP represents a significant advancement in treatment strategies. This approach aims to optimize pain relief, reduce opioid consumption, and enhance the overall quality of life for patients grappling with this complex condition.[ 13 ] A multimodal pain management strategy that combines SHPB with pharmacological treatments has demonstrated promising outcomes. Research indicates that patients receiving SHPB in conjunction with traditional medications experience substantial reductions in pain scores and improved quality of life compared to those who rely solely on pharmacological interventions. Establishing personalized protocols for these repeated blocks can help ensure sustained relief and prevent the recurrence of debilitating symptoms.[ 17 ] The integration of the SHPB with conventional therapies in CPP management is summarized in Table 2 . Integration of superior hypogastric plexus block with conventional therapies in chronic pelvic pain management Recent advancements in the SHPB delivery have significantly enhanced its efficacy and safety profile. One of the most notable innovations is the integration of advanced imaging modalities such as fluoroscopy and ultrasound. Fluoroscopy provides real-time visualization of anatomical structures, ensuring precise needle placement during the procedure.[ 26 ] Technological advancements and future directions in the SHPB are summarized in Table 3 . Technological advancements and future directions in superior hypogastric plexus block Clinicians should thoroughly evaluate patients’ suitability for the SHPB procedure. Candidates must have a confirmed diagnosis of CPP, ideally with identifiable underlying conditions such as endometriosis, pelvic inflammatory disease, or neuropathic pain.[ 13 ]

The integration of SHPB with conventional therapies represents a promising advancement in the management of CPP. There are no conflicts of interest.